Successful Conversion From Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium (Myfortic) in Liver Transplant Patients With Gastrointestinal Side Effects

Transplantation Proceedings

Volumn 41, Issue 2, 2009, Pages 610-613

  Robaeys, G ^a   Cassiman, D ^a   Verslype, C ^a   Monbaliu, D ^a   Aerts, R ^a   Pirenne, J ^a   Nevens, F ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DEFECATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTERIC COATED TABLET; FECES; FEMALE; GASTROINTESTINAL PAIN; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MACROCYTIC ANEMIA; MALE; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOCYTOPENIA; VISUAL ANALOG SCALE;

ADOLESCENT; ADULT; AGED; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PAIN; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; TABLETS, ENTERIC-COATED; YOUNG ADULT;

EID: 62849111963     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.12.021     Document Type: Article

References (9)

1. Arslan H., Inci E.K., Azap O.K., et al. Etiologic agents of diarrhoea in solid organ recipients. Transpl Infect Dis 9 (2007) 270
2. Calvo N., Sanchez-Fructuoso A.I., Conesa J., et al. Renal transplant patients with gastrointestinal intolerability to mycophenolate mofetil: conversion to enteric-coated mycophenolate sodium. Transplant Proc 38 (2006) 2396
3. Bolin P., Tanriover B., Zibari G.B., et al. Improvement in 3-month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients. Transplantation 84 (2007) 1443
4. Chan L., Mulgaonkar S., Walker R., et al. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 81 (2006) 1290
5. Dumortier J., Gagnieu M.C., Salandre J., et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients presenting gastrointestinal disorders: a pilot study. Liver Transpl 12 (2006) 1342
6. Cantisani G.P., Zanotelli M.L., Gleisner A.L., et al. Enteric-coated mycophenolate sodium experience in liver transplant patients. Transplant Proc 38 (2006) 932
7. Miras M., Carballo F., Egea J., et al. Clinical evolution in the first 3 months of patients after liver transplantation in maintenance phase converted from mycophenolate mofetil to mycophenolate sodium due to gastrointestinal complications. Transplant Proc 39 (2007) 2314
8. Arns W. Noninfectious gastrointestinal (GI) complications of mycophenolic acid therapy: a consequence of local GI toxicity. Transplant Proc 39 (2007) 88
9. Maes B.D., Dalle I., Geboes K., et al. Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea. Transplantation 75 (2003) 665